National practice patterns and time trends in androgen ablation for localized prostate cancer. - Wikidata - awgldk - TriplyDB

National practice patterns and time trends in androgen ablation for localized prostate cancer.

National practice patterns and time trends in androgen ablation for localized prostate cancer.

http://www.wikidata.org/entity/Q34363769

about

Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review Outcomes of localized prostate cancer following conservative management Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?Management of patients with biochemical recurrence after local therapy for prostate cancer Quality of life issues in men undergoing androgen deprivation therapy: a review Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study.Time trends and local variation in primary treatment of localized prostate cancer Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer Redefining hormone resistance in prostate cancer.Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.Challenges in clinical prostate cancer: role of imaging.Use of androgen deprivation therapy for metastatic prostate cancer in older men.Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection.Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.Contemporary role of androgen deprivation therapy for prostate cancer Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer: surgical and oncological outcomes in men aged ≥70 years.Energetics in colorectal and prostate cancer.Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art.Androgen deprivation therapy for prostate cancer: new concepts and concerns.Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.Quantifying the role of PSA screening in the US prostate cancer mortality decline.Management of complications of androgen deprivation therapy in the older man.Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study.The example of CaPSURE: lessons learned from a national disease registry Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.Risk stratification in the hormonal treatment of patients with prostate cancer Hormone therapy in the management of prostate cancer: evidence-based approaches The war on cancer: a report from the front lines Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer Utility of FDG-PET in clinical neuroendocrine prostate cancer.Androgen deprivation therapy and cardiovascular risk.Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database.Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.

P2860

Q24597422-47F6DCED-7C18-42F4-A286-C96CBACA2352 Q24647380-5EB152DB-5DA2-4DA8-B7D1-5682F4BEB8F5 Q26801132-E6DC2948-2E6B-4BA1-B2E2-6EB1F276759D Q26849220-50FE7E46-E4BF-4A92-9BD2-DA76B50D20A4 Q27002887-8A5BD7B4-BDB6-4E66-9DF8-027956AEE07B Q33351115-82FA3334-397F-485D-8378-5BE56CE80DEB Q33443421-BC8555A5-AC16-48B1-87EC-DF776FC5FD66 Q33677118-50EF6643-1790-4F9E-AE28-A65B66FDAA01 Q33710948-6044EF56-0CA3-441D-92A7-1476908C3E2B Q33763924-4884E4C9-DFC1-40BC-B703-5EB31CC2A108 Q33899266-D4755E7B-BC36-443F-8DD9-FC5BC5715C5F Q33903836-89E6D569-D4B9-4095-9F07-F2FDFFF31A71 Q33926384-15B0F0F4-D990-494E-913E-B5EE4969D79F Q33945133-4F710246-D8F4-4842-84CA-272B41CF8754 Q33977514-D4F70F49-E83D-4A8E-A3F2-E14F05E117B1 Q34017719-E5A447B2-190B-4969-A4AC-154A156DD647 Q34143921-A449EA59-B045-4A86-B596-ACF835A595C0 Q34211155-3855BBFD-CAB4-424B-B9A4-9653C8E00CEB Q34288796-BEBE1168-883E-4902-AF2D-FD675E4612E0 Q34294893-ABA30952-1025-4926-9800-5C7E9CE33E44 Q34315768-ADDA54EC-B734-43FB-AB71-FD9C9A510E24 Q34417815-7A2BA606-F0C7-45C0-ADB2-B662439BA691 Q34617845-597A2BC5-5090-4ECE-9DCE-7F74AAE9582D Q34617924-1B26175D-C479-4128-ADAE-300A5529C378 Q34720042-33F69C37-FF71-448C-AE4A-F487F82E1C67 Q34782101-6A75C291-F1D3-4860-9CE3-C7886C7F190B Q34810730-B421ADCC-31B9-401C-9D85-A71055054802 Q34960686-923C37A3-FC06-415C-8569-640F98497085 Q34984105-6E1D7451-7676-431A-8A46-484A3530262C Q34996369-FDF2CEFD-93D8-48C5-B18A-04DB08067F60 Q35022837-004714EB-6060-4CAC-93C7-400E28B9E32B Q35076189-F6F52AC1-52DB-44A0-8525-962E4900A26A Q35076432-C8320E0B-023E-48F3-9068-7DEB1C256506 Q35103643-D2771DDA-7846-4CE9-B1C9-4578DB749F52 Q35147527-430333AD-CFA1-4686-8B94-D2B0E4B96C41 Q35166475-7E4E0A22-B227-49F2-A4F3-BA6D29AA2432 Q35229730-C96A9130-394A-4FA3-8CDA-705911D65E42 Q35231126-B4062569-866C-43D4-8B55-E10DF40E28AB Q35635497-829B907D-2532-49B9-9AA5-C15C641CB76B Q35754343-5A2E972F-572B-431F-8C14-746ED9BC6B7B

P2860

National practice patterns and time trends in androgen ablation for localized prostate cancer.

http://www.wikidata.org/entity/Q34363769

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

National practice patterns and ...... for localized prostate cancer.

@ast

National practice patterns and ...... for localized prostate cancer.

@en

National practice patterns and ...... for localized prostate cancer.

@nl

type

label

National practice patterns and ...... for localized prostate cancer.

@ast

National practice patterns and ...... for localized prostate cancer.

@en

National practice patterns and ...... for localized prostate cancer.

@nl

prefLabel

National practice patterns and ...... for localized prostate cancer.

@ast

National practice patterns and ...... for localized prostate cancer.

@en

National practice patterns and ...... for localized prostate cancer.

@nl

P1433

Q34363769-11860DED-9B62-4962-9C05-AD850D889E3B

P1476

Q34363769-0810171C-EDEB-4964-AE76-ABBAC1F25620

P2093

Q34363769-45839C01-739A-4314-914C-E04E840F5124

Q34363769-A5214215-2B83-4C74-A6AE-E681A7AACB51

Q34363769-D8406E86-9F17-4220-9A18-0BA26632E136

P2860

Q34363769-0062F1A0-C666-45BE-8355-3FC1D7204130

Q34363769-233E6822-C2F4-4E78-BBBA-4E0731622E6B

Q34363769-2FF8758E-1280-4D20-86B6-A330499E1145

Q34363769-3BECB47E-A2F2-4FF9-B221-CE2A889EB4FC

Q34363769-438B2260-DF5F-4E33-9842-CA26C6629CC7

Q34363769-4B56D773-F880-43AD-9A6F-A5D97471086F

Q34363769-4C193D8B-C0E2-48F2-9898-31406855CA75

Q34363769-5AA5A22D-3630-4882-880A-120DA44FF709

Q34363769-5D6599EE-3BD9-4BBF-8C56-8796D8285C87

Q34363769-692C3F99-F096-47F4-9016-F69AC43928AD

P304

Q34363769-895BBCF9-AAE3-4919-8ABE-043D8EB8A8E2

P31

Q34363769-692738B2-9462-4CE5-B5C9-AF1AB6DE97CA

P356

Q34363769-CF03DB86-F0ED-4700-81BF-04A5199641A3

P407

Q34363769-AECE5538-00A8-45D4-A01D-D6EC7D8EB841

P433

Q34363769-C6477840-FF55-4505-9DAA-6E881769C0CC

P478

Q34363769-08F2C22C-F66C-4A1A-BC49-DB13A681ACE1

P50

Q34363769-F579616D-003D-4D35-9D2A-BD578614EBCC

P577

Q34363769-79988986-C15C-47DD-AF1A-58B8EACAD861

P5875

Q34363769-25153205-255F-46AD-B744-38CED4E70081

P698

Q34363769-2956F0AF-A831-4208-9493-E56F31E8A78A

P932

Q34363769-EBBB6A8D-3FFC-4075-BA5D-F3BBC0EC0DBC

P356

P1433

Journal of the National Cancer Institute

P1476

National practice patterns and ...... for localized prostate cancer.

@en

P2093

Deborah P Lubeck

http://www.w3.org/2001/XMLSchema#string

Gary D Grossfeld

http://www.w3.org/2001/XMLSchema#string

Peter R Carroll

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database.

Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).

Neoadjuvant hormonal therapy in carcinoma of the prostate.

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer.

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.

Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database.

Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.

Critical evaluation of hormonal therapy for carcinoma of the prostate.

Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor.

P304

981-989

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/95.13.981

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

Matthew R Cooperberg

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10680718

http://www.w3.org/2001/XMLSchema#string

P698

12837834

http://www.w3.org/2001/XMLSchema#string

P932

2994265

http://www.w3.org/2001/XMLSchema#string